Form 4: Ligand Pharma Director Sells Shares After Option Exercise

Ligand Pharmaceuticals Director Nancy Ryan Gray exercised stock options and immediately sold the acquired shares, maintaining her beneficial ownership at 8,094 shares.

Summary

• Director Nancy Ryan Gray exercised two sets of non-qualified stock options on November 7, 2025.
• The first exercise involved 3,556 shares of common stock at an exercise price of $66.19 per share.
• The second exercise involved 3,015 shares of common stock at an exercise price of $73.57 per share.
• Immediately following the exercises, Gray sold all 6,571 acquired shares (3,556 + 3,015) at a price of $205.45 per share.
• Her beneficial ownership of Ligand Pharmaceuticals common stock remains 8,094 shares after these transactions.
• The options were adjusted from their original grant amounts and exercise prices due to the OmniAb Inc. separation from the issuer.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a standard insider exercise and sale, indicating personal financial planning rather than a strong positive or negative signal about the company's future performance.

Positives

• Director exercised options at significantly lower prices ($66.19 and $73.57) compared to the sale price ($205.45), indicating a substantial personal gain.
• The sale price of $205.45 per share suggests a strong market valuation for LGND stock at the time of the transaction.

Negatives

• An insider selling shares, even after an option exercise, could be interpreted by some investors as a lack of conviction in the stock's future appreciation, although it is often for personal liquidity or diversification.

Future Outlook

NA

Industry Context

This transaction is a routine insider filing, common for directors exercising vested stock options for personal financial planning or diversification. It does not inherently reflect broader industry trends but rather individual compensation and liquidity events.

Related Party Transactions

• The reported transactions are related party transactions as they involve a director of the issuer. These are standard compensation-related transactions.

Stakeholder Impact

• Shareholders: The sale by a director could be viewed neutrally or slightly negatively, depending on individual investor interpretation of insider selling. However, the exercise of options at a much lower price and subsequent sale at a higher market price demonstrates the value of the company's equity compensation program.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director exercised stock options and immediately sold the acquired shares. Such transactions are typically for personal liquidity or diversification and do not inherently signal a change in the company's fundamental prospects. The significant spread between the exercise price and sale price indicates the options were in-the-money, which is positive for the director's compensation but provides no new information about the company's operational performance or future outlook. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a change in investment thesis.

Keywords

Ligand Pharmaceuticals, LGND, Insider Trading, Form 4, Stock Options, Director Sale, Equity Transaction, Nancy Ryan Gray